Table 2. Studies reviewed in this article.

CP: Cerebral Palsy; BM: Bone Marrow; BMMSCs: Bone Marrow Mesenchymal Stem Cells; BM-MNC: Bone Marrow Mononuclear Cell; UCB: Umbilical Cord Blood; hUCB: Human Umbilical Cord Blood; NSCs: Neural Stem Cells.

Author Name and Year of publication	PURPOSE	Type of study and number of subjects included (n)	CELL TYPE	ROUTE	DOSAGE	DURATION	CONCLUSION
Himanshu et al., 2016 [31]	Autologous Bone marrow-derived stem cells for the treatment of CP	Clinical Trial. n=10	BM-derived Mesenchymal stem cells	Into subarachnoid cavity	4.5 × 108 mononuclear cells; 90% viability	24 months follow up	Significant gross motor function improvement higher at month six post-treatment compared with the baseline scores and were stable up to 24 months follow-up.
Xuebin Liu et al., 2017 [35]	Comparative analysis between BM mesenchymal and BM mononuclear Stem cells in the treatment of Spastic CP	Randomized control Trail; n=105	BMMSCs  BMMNCs	Intrathecal infusion	1 × 106/kg body weight. Four Doses	12months	BMMSCs cells are safe and better improvement of Gross Motor function compared to BMMNCs
Than Leim Nguyen et al., 2018 [34]	Effect of BMMNCs treatment on quality of life in CP patients	Open-Label Uncontrolled Clinical Trial; n=30	BMMNCs	Intrathecal infusion	8 mL/kg for patients weighing less than 10 kg and [80 mL+(bodyweight in kg-10) × 7 mL], but not exceeding 200 mL in total, for patients weighing more than 10 kg.	12 months	There's been a noticeable improvement in the quality of life in patients with CP who were treated with BMMNC transplantation for six months period, especially improving gross motor function and muscle tone.
Jessica M. Sun et al., 2017 [29]	Effect of Autologous Cord blood on Motor function and brain connectivity in Young CP patients	Double-blind placebo control Cross Over Study; n=63	Autologous Cord Blood cells	Intravenous infusion	Single-dose 1–5 × 107 total nucleated cells per kilogram of ACB,	24 months (12 months cross over)	when dosed ≥two × 107 cells per kg, an IV infusion of ACB improves whole-brain connectivity and motor function in young children with CP.
Mino Kang et al., 2015 [32]	Involvement of immune response in the efficacy of cord blood cell therapy for CP	Randomized control Trial; n=36	UCB	--------	---------	Six months	In this trial, UCB alone has shown to have a good improvement in gross motor function, inducing systemic immune reactions, and anti-inflammatory changes in the brain. Motor function was directly proportional to and positively correlated by the number of UCB cells administered; Concluding that the better outcome depended on the number of cells infused.
Li Huang et al., 2018 [24]	Human umbilical stem cell infusion therapy for CP patients	Randomized Placebo Control Trail; n=54	HUCB - MSCs	Intravenous infusion	Four doses of 5 × 107 cells/kg	24 months	hUCB-MSC infusion, along with basic rehabilitation, shown to be more safe and effective in improving gross motor function in children with CP compared to basic rehabilitation alone. nevertheless, it might not be realistic in improving neurologic function through replacement by hUCB-MSC infusion IV, considering the limited quantity of MSCs through the blood-brain barrier(BBB)
Liem Than Nguyen et al., 2017 [33]	Autologous bone marrow transplant for CP	Open Labeled Uncontrolled Clinical Trial; n=40	BMMNCs	Intrathecal	8 mL/kg for patients weighing <10 kg and [80 mL+(bodyweight in kg-10) × 7 mL], but not exceeding 200 mL in total, for patients weighing >10 kg.  Two doses	12 months	Autologous bone marrow mononuclear cell transplantation showed to be more effective and safer for patients suffering from cerebral palsy
Guogun Chen et al.; 2013 [36]	Neural Stem Cell like Cells derived from Autologous Bone Mesenchymal Stem Cells for CP	Non-Randomized Clinical Trail; n=60	Autologous BM-NSC like cells	Subarachnoid cavity	1-2 107cells	6months	NSC like cells are safe and effective for the treatment of motor deficits related to CP